Press releases - Ypsomed

Dr. Nicolas Meyer succeeds Dr. Beat Maurer on the Executive Board

03/30/2023 - 7:00am Press Releases Ypsomed Group

Burgdorf – Ypsomed announces a change in its Executive Board. After more than thirty years with Ypsomed and formerly Disetronic, Dr Beat Maurer will retire as Chief Legal Officer (CLO) on 31 March 2023. He will be succeeded by Dr Nicolas Meyer, who will take up the position as CLO at Ypsomed on 01 May 2023.

Topics:

Management

mylife Loop offers new remote monitoring feature for parents

02/22/2023 - 7:00am Press Releases Ypsomed Group

Burgdorf – Parents and caregivers of children with diabetes can now follow their child's glucose and insulin data via the mylife CamAPS FX app on their own personal smartphone. The new "Companion remote monitoring" feature is fully integrated into the app. It gives parents and caregivers better control and peace of mind.

Topics:

Innovation & Digital Health

machine MD - Winner of the Ypsomed Innovation Award 2022

Winners of the Ypsomed Innovation Award 2022 announced

01/11/2023 - 11:00am Press Releases Ypsomed Group

Burgdorf - The winners of the Ypsomed Innovation Award 2022 were honoured yesterday evening at the PwC Switzerland New Year's Apéro in Bern. The winners are machineMD (1st place), Pace Locator (2nd place) and Compact Motion (3rd place). The Innovation Award, worth a total of CHF 100,000, is presented every two years by the Ypsomed Innovation Fund Foundation. The aim is to promote the transfer of knowledge and technology from universities of applied sciences and universities in the "Espace Mittelland" region.

Topics:

Innovation & Digital Health

Ypsomed and Mediq complete the sale of DiaExpert

01/03/2023 - 7:00am Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) and Mediq are completing the sale of DiaExpert. The transaction strengthens Ypsomed's focus on the development, manufacture and distribution of its own high-quality medical technology products for people with chronic conditions.

Eli Lilly is focusing on its successful drug portfolio and is halting its ambition to enter insulin pump business. Ypsomed remains committed to its US YpsoPump ambitions with a new partner.

12/09/2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Eli Lilly and Company (NYSE: LLY) has decided to fully focus on its successful drug portfolio. Therefore, Lilly decided to stop the joint project with Ypsomed (SIX: YPSN) to enter the US insulin pump market in 2026. Ypsomed plans to submit its YpsoPump system to the FDA in the second half of 2023 according to plan, and subsequently commercialize the system with a new partner.